BAAR, Switzerland, March 12, 2025--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the ...

Working from findings in the landmark TAILORx study, reseachers estimated that Oncotype DX-guided treatment could reduce the total first-year breast cancer care by nearly $50 million across the United ...

Evaluation of androgen receptor expression in pretreatment, posttreatment and recurrent breast cancer patients. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does ...

A new study suggests that Oncotype DX-guided treatment could reduce the cost for the first year of breast cancer care in the US by about $50 million (about 2 percent of the overall costs in the first ...

Please provide your email address to receive an email when new articles are posted on . Under ideal conditions— in which all patients received the test and all physicians and patients used the results ...

In a simple definition, cancer is a disease of the cells, which is caused by gene mutations. For a proportion of patients, including women with hormone receptor positive (HR+) breast cancer, gene ...

In the new era of personalized medicine, having more information on hand is considered the ideal situation for making more customized, and ideally, effective decisions about medical care. And in a new ...

Title: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC. Presenter: Ivana Sestak, Ph.D. Date: Friday, Dec.9, 2016: 4:15 p.m. CT. Location: S6-05; General Session 6 - ...

Breast cancer is the most common non-cutaneous cancer in women, and the second most frequent cause of cancer death among women. 1 Approximately 50% of breast cancer cases are estrogen receptor ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score ...